DR REDDYS LABORATORIES LTD RDY

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2026 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2026FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue —$3.81B$3.35B$2.99B$2.83B$2.59B$2.32B$2.23B$2.18B
Operating income —$842.0M$813.0M$695.0M$389.0M$332.0M$212.0M$302.0M$183.0M
Net income —$671.0M$668.0M$548.0M$311.0M$236.0M$259.0M$272.0M$151.0M

Balance sheet

Fiscal year FY2026FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets —$5.77B$4.65B$3.92B$3.86B$3.63B$3.08B$3.26B$3.46B
Total equity —$3.95B$3.37B$2.81B$2.51B$2.37B$2.06B$2.03B$1.94B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001575872-26-000381.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 1B 2B 3B 4B Revenue, FY2017: 2.2B Net income, FY2017: 151M Revenue, FY2018: 2.2B Net income, FY2018: 272M Revenue, FY2019: 2.3B Net income, FY2019: 259M Revenue, FY2020: 2.6B Net income, FY2020: 236M Revenue, FY2021: 2.8B Net income, FY2021: 311M Revenue, FY2022: 3B Net income, FY2022: 548M Revenue, FY2023: 3.4B Net income, FY2023: 668M Revenue, FY2024: 3.8B Net income, FY2024: 671M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2026
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2026
Revenue $2.18B $2.23B $2.32B $2.59B $2.83B $2.99B $3.35B $3.81B —
Gross profit — — — — — — — — —
Net income $151.0M $272.0M $259.0M $236.0M $311.0M $548.0M $668.0M $671.0M —

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%